Need Help?

Human melanoma samples with and without resistance to BRAF inhibitor therapy

Human melanoma samples were collected pre, on, and progression on BRAF inhibitor therapy. RNA was extracted and run on RNA-seq. This has provided insights into different categories of BRAF inhibitor resistance mechanisms.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001306 Illumina HiSeq 2000 38
Publications Citations
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
J Clin Invest 126: 2016 1834-1856
Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
Oncotarget 8: 2017 25395-25417
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Nat Commun 8: 2017 607
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Nature 550: 2017 133-136
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
EMBO Mol Med 10: 2018 e8446
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.
J Clin Invest 128: 2018 3976-3990
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors.
Front Oncol 10: 2020 757
Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells.
Cancers (Basel) 12: 2020 E2218
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.
Nat Commun 11: 2020 5463
Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases.
Sci Rep 11: 2021 7847
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Nat Commun 12: 2021 5505
Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma.
Front Pharmacol 13: 2022 928226
Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Front Immunol 14: 2023 1176994